Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Date:7/31/2014

ense. 

Total operating costs and expenses in the second quarter of 2014 were $51.4 million as compared to $66.5 million in the second quarter of 2013.  Total operating costs and expenses in the first half of 2014 were $107.6 million as compared to $134.6 million in the first half of 2013.  Total operating costs and expenses decreased primarily as a result of decreased research and development (R&D) expense, as well as decreased cost of goods sold associated with decreased manufacturing activity.

Research and development expense in the second quarter of 2014 was $36.7 million as compared to $52.2 million in the second quarter of 2013.  For the first half of 2014, R&D expense was $75.0 million as compared to $97.8 million in the first half of 2013.  R&D expense was lower in the second quarter and first half of 2014 as compared to the same periods in 2013 primarily because of reduced expenses for the Phase 3 study of etirinotecan pegol (NKTR-102) in metastatic breast cancer, which completed enrollment in the third quarter of 2013. Additionally, R&D expense in the second quarter and first half of 2013 included costs related to the Phase 2 study of NKTR-181, which was completed in 2013.  These decreases in R&D expense in 2014 were partially offset by costs for the preparation for the start of Phase 3 for NKTR-181, the ongoing Phase 1 study of NKTR-171, and the continued production of devices for the ongoing Phase 3 studies of Amikacin Inhale.

General and administrative expense was $9.6 million in the second quarter of 2014 as compared to $9.2 million in the second quarter of 2013.  G&A expense in the first half of 2014 was $19.5 million as compared to $20.1 million in the first half of 2013.

Non-cash interest expense incurred in connection with the 2012 royalty monetization was $5.1 million and $10.5 million in the second quarter and first half of 2014, respectively, as compared to $
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
4. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
7. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
11. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Lupin , Strides , ... Sub-licensees to Fourteen Companies     ... of its network of generic manufacturers to 14 companies now ... (ARVs). New companies Lupin and Strides Arcolab recently signed agreements ... MPP licensed from ViiV Healthcare two months after its approval ...
(Date:7/1/2015)... 2015 Research and ... the "Future Horizons and Growth Strategies in ... and Country Forecasts" report to their offering. ... the European Blood Banking Market 2015 is a ... current suppliers and potential market entrants identify and ...
(Date:7/1/2015)... DIEGO , July 1, 2015  AVACEN, Inc. announced ... second AVACEN patent covering the medical technology platform supporting its ... Logo - http://photos.prnewswire.com/prnh/20150630/227364LOGO ... apparatus and methods patent no. 9,066,781 - Methods And Apparatus ... manufactured by AVACEN and specific methods of use, referred to ...
Breaking Medicine Technology:The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs) 2The Medicines Patent Pool Increases its Generic Manufacturing Network to Ramp-Up Production of Low Cost Antiretrovirals (ARVs) 3European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 2European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 3AVACEN Medical Patent Issued 2
... June 1 Reportlinker.com announces that a new market research report is available in its catalogue: , ... China Patient Monitoring Market Outlook to 2016 , , , ... , , China Patient Monitoring Market Outlook ... Summary , , , ...
... LIUZHOU CITY, Guangxi, China ... Group, Inc., (OTC Bulletin Board: CNBI), ("China BCT" or ... pharmaceutical products in Guangxi Province , China ... stores in Laibin,City, Xiangzhou County, further expanding the Company,s ...
Cached Medicine Technology:Reportlinker Adds China Patient Monitoring Market Outlook to 2016 2Reportlinker Adds China Patient Monitoring Market Outlook to 2016 3Reportlinker Adds China Patient Monitoring Market Outlook to 2016 4Reportlinker Adds China Patient Monitoring Market Outlook to 2016 5Reportlinker Adds China Patient Monitoring Market Outlook to 2016 6Reportlinker Adds China Patient Monitoring Market Outlook to 2016 7Reportlinker Adds China Patient Monitoring Market Outlook to 2016 8Reportlinker Adds China Patient Monitoring Market Outlook to 2016 9Reportlinker Adds China Patient Monitoring Market Outlook to 2016 10Reportlinker Adds China Patient Monitoring Market Outlook to 2016 11Reportlinker Adds China Patient Monitoring Market Outlook to 2016 12Reportlinker Adds China Patient Monitoring Market Outlook to 2016 13Reportlinker Adds China Patient Monitoring Market Outlook to 2016 14Reportlinker Adds China Patient Monitoring Market Outlook to 2016 15Reportlinker Adds China Patient Monitoring Market Outlook to 2016 16Reportlinker Adds China Patient Monitoring Market Outlook to 2016 17Reportlinker Adds China Patient Monitoring Market Outlook to 2016 18Reportlinker Adds China Patient Monitoring Market Outlook to 2016 19Reportlinker Adds China Patient Monitoring Market Outlook to 2016 20Reportlinker Adds China Patient Monitoring Market Outlook to 2016 21Reportlinker Adds China Patient Monitoring Market Outlook to 2016 22Reportlinker Adds China Patient Monitoring Market Outlook to 2016 23Reportlinker Adds China Patient Monitoring Market Outlook to 2016 24China BCT Acquires 11 Stores, Expanding Retail Pharmacy Network 2China BCT Acquires 11 Stores, Expanding Retail Pharmacy Network 3
(Date:7/2/2015)... ... July 02, 2015 , ... Evolved Ayurvedic Discoveries , ... an intention to partner with companies that share a similar mission of providing ... water soluble, Cannabidiol (CBD) formulations, combined with Ayurvedic herbs, are now available for ...
(Date:7/2/2015)... , ... July 02, 2015 , ... Today, East Liverpool ... the Surgical Center at East Liverpool City Hospital (ELCH). Pam is currently the Chief ... of the director of surgery. Pam holds a master’s degree in health care administration ...
(Date:7/2/2015)... ... ... As part of the celebration of its 70th anniversary, the Thantakit International ... all around the world for their continuous patronage of the world-class services of their ... (indeed, Thantakit is one of the foremost places for dental tourism in Thailand) or ...
(Date:7/2/2015)... ... , ... Maddock Douglas is an internationally recognized firm that ... manage the increasing demand for innovation as a primary growth strategy, Maddock Douglas ... , Benkendorf is a seasoned management executive with more than 25 years of ...
(Date:7/1/2015)... ... July 01, 2015 , ... Dr. ... Georgia State University and a Georgia Research Alliance Eminent Scholar in Inflammation and ... therapeutics against middle-ear infections. , The grant from the National Institute on Deafness ...
Breaking Medicine News(10 mins):Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 2Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 3Health News:East Liverpool City Hospital Announces New Surgical Center Leadership 2Health News:East Liverpool City Hospital Announces New Surgical Center Leadership 3Health News:Thailand's Longest Established International Dental Center Celebrates Its 70th Anniversary with Promos Galore 2Health News:Business Builder Mark Benkendorf Joins Innovation Firm Maddock Douglas 2Health News:Institute for Biomedical Sciences Researcher Gets $1.6 Million to Develop Anti-Inflammatory Drug 2
... 15, 2007 The U.S. Pharmacopeia (USP) is ... dietary supplements for public notice and comment. ... Isoflavones monographs appeared in Pharmacopeial Forum (PF) 33(6), ... Turmeric, Powdered Turmeric, Powdered Turmeric Extract, Curcuminoids, Curcuminoids ...
... Nov. 15 Medical Services,International Inc. (Pink Sheets: MSITF) ... excellent independent test results obtained by regulatory,agencies related to ... the dual,VScan test kit that detects HIV and TB ... to be closely associated. It is very difficult to,get ...
... Launches Highly Accessible and ... Affordable Program ... YORK, Nov. 15 Chefs Diet(R), the leading meal,delivery service provider based ... My Solution -- a nationwide program that provides,chef-prepared, gourmet frozen meals for ...
... for Driver Safety Highlighted, WASHINGTON, Nov. 15 ... will hit the roads to spend time,with family and ... of the,11 million Americans with uncorrected vision problems. Depending ... could have,been eighteen years ago and some may never ...
... a study of more than 6,000 Los Angeles-area children ... Keck School of Medicine of the University of Southern California ... wall-eyed) and amblyopia (often referred to as lazy eye) were ... The study is currently available in the online edition of ...
... of men co-infected with herpes simplex virus type 2 (HSV-2) ... the levels of HIV in the blood and rectal secretions, ... This study is published in the November 15 issue ... , Most HIV-infected persons are also infected with HSV-2, ...
Cached Medicine News:Health News:USP announces 11 new proposed monographs for dietary supplements 2Health News:Medical Services Gets Significant Interest in Its Dual VScan Test Kit 2Health News:CHEFS DIET(R) Introduces My Solution 2Health News:Report Shows Millions May Be Driving with Uncorrected Visual Impairments 2Health News:Report Shows Millions May Be Driving with Uncorrected Visual Impairments 3Health News:USC study -- largest of its kind -- finds older children more likely to develop vision disorders 2Health News:Study shows suppressing herpes virus may reduce infectiousness of HIV 2
... of Alcon Acrylic, Chiron/Iolab LI-41 and Pharmacia & ... taller and thinner, maximizing the surface area around ... during loading and insertion, and makes it easy ... lens optic. The special direct-acting jaws release the ...
... 599 is the first full-featured combination automatic ... response on refraction results with visual acuities. ... at either 90 or 180 to accommodate ... HARK to the Humphrey Lens Analyzers for ...
Neomycin and Polymyxin B Sulfates and Hydrocortisone otic suspension, USP is a sterile antibacterial and anti-inflammatory suspension for otic use....
Prednisolone Acetate ophthalmic suspension USP, 1% is an adrenocortical steroid product prepared as a sterile ophthalmic suspension....
Medicine Products: